All In Biotech

Drug Trial Radar · NCT01939002

Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)

An Open-Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017

Last checked: Nov 20, 2026Latest source record: Jan 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

251

Actual

Start

Nov 2013

Primary completion

Oct 2015

Study completion Nov 2015

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Sep 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the proportion of participants with relapsing multiple sclerosis who experience new and/or increased flu-like symptoms (FLS) after transitioning from nonpegylated IFN-β therapies to peginterferon beta-1a (BIIB017). Secondary objectives are: to determine the severity and frequency (measured by flu-like symptom score \[FLS-S\]) of FLS in these participants; to determine the duration (measured in number of hours) of FLS in these participants; to determine the effect of BIIB017 on other participant-reported outcomes, including treatment satisfaction (measured with the Treatment Satisfaction Questionnaire for Medication \[TSQM\]) and disability status (measured with the Patient Determined Disease Steps \[PDDS\]) over a 56-week period; to determine whether interferon-related FLS result in missed days of work/daily activities (e.g., absenteeism); to assess the use of additional medications (in addition to current medications used to treat FLS) to relieve BIIB017-related FLS; to determine the incidence of adverse events throughout the study period; to characterize the immunogenicity profiles of participants switching from prior IFN-β therapy to BIIB017.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • BIIB017Drug

  • naproxenDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing New or Increased FLS During the First 8 Weeks: Overall PopulationTime frame: during the first 8 weeks of treatment

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Gilbert, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Boulder, Colorado

  • Research Site

    Fort Collins, Colorado

  • Research Site

    Dover, Delaware

  • Research Site

    Newark, Delaware

  • Research Site

    Jacksonville, Florida

  • Research Site

    Melbourne, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Kansas City, Kansas

  • Research Site

    Lexington, Kentucky

  • Research Site

    Louisville, Kentucky

  • Research Site

    Boston, Massachusetts

  • Research Site

    Lexington, Massachusetts

  • Research Site

    Worcester, Massachusetts

  • Research Site

    Detroit, Michigan

  • Research Site

    Chesterfield, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Great Falls, Montana

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Latham, New York

  • Research Site

    Plainview, New York

  • Research Site

    Asheville, North Carolina

  • Research Site

    Akron, Ohio

  • Research Site

    Dayton, Ohio

  • Research Site

    Uniontown, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Portland, Oregon

  • Research Site

    Greenville, South Carolina

  • Research Site

    Franklin, Tennessee

  • Research Site

    Knoxville, Tennessee

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Newport News, Virginia

  • Research Site

    Roanoke, Virginia

  • Research Site

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.